drugset / Trial / NCT03111992
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2017-12-18
- Primary completion
- 2020-03-02
- Completion
- 2020-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CJM112 | Monoclonal antibody | — | — |
| Subject | LCL161 | Small molecule | — | Oral |
| Subject | Spartalizumab | Monoclonal antibody | — | — |